REGENXBIO
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell REGENXBIO and other ETFs, options, and stocks.About RGNX
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381.
CEOCurran M. Simpson
CEOCurran M. Simpson
Employees353
Employees353
HeadquartersRockville, Maryland
HeadquartersRockville, Maryland
Founded2008
Founded2008
Employees353
Employees353
RGNX Key Statistics
Market cap446.18M
Market cap446.18M
Price-Earnings ratio-2.84
Price-Earnings ratio-2.84
Dividend yield—
Dividend yield—
Average volume1.49M
Average volume1.49M
High today$9.09
High today$9.09
Low today$8.42
Low today$8.42
Open price$8.58
Open price$8.58
Volume825.23K
Volume825.23K
52 Week high$16.25
52 Week high$16.25
52 Week low$5.04
52 Week low$5.04
RGNX News
Simply Wall St 4d
REGENXBIO Inc. Just Missed EPS By 64%: Here's What Analysts Think Will Happen NextIt's shaping up to be a tough period for REGENXBIO Inc. ( ), which a week ago released some disappointing first-quarter results that could have a notable impact...
TipRanks 6d
REGENXBIO Reports Strong Q1 2025 Financial ResultsRegenXBio Inc. ( (RGNX) ) has released its Q1 earnings. Here is a breakdown of the information RegenXBio Inc. presented to its investors. Protect Your Portfoli...
Analyst ratings
92%
of 13 ratingsBuy
92.3%
Hold
7.7%
Sell
0%
People also own
Based on the portfolios of people who own RGNX. This list is generated using Robinhood data, and it’s not a recommendation.